Synthekine

Synthekine is proud to be chosen as one of this year's Fierce 15 winners! We are honored to be named as one of the most promising early-stage biotechnology companies in the industry. Thank you, Fierce Biotech, for recognizing the work of our amazing team and our mission to develop the next generation of #cytokine therapeutics. Learn more: https://lnkd.in/e85ZGXyY   #Fierce152022 #Fierce15 #Biotech

Today, we presented positive translational data from the Phase 1a/1b #ClinicalTrial of STK-012, our first-in-class α/β-IL-2R biased partial agonist at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting in Houston. These data further demonstrate the mechanism of action of STK-012 and its ability to selectively induce T cell activation and expansion.     Additionally, we will present at SITC preclinical and GLP toxicology data on STK-026, our biased IL-12 cytokine partial agonist also designed for preferential activity on T cells.      Read the full press release: https://lnkd.in/ghhNdr-2

We look forward to presenting data from multiple abstracts at the 12th Annual Meeting of the International Cytokine & Interferon Society (ICIS) jointly held with the Korean Association of Immunologists (KAI) International Meeting this month! Don’t miss the opportunity to hear our team discuss Synthekine’s cutting-edge pipeline of innovative #cytokine therapeutics. See our poster and presentation details below:     #Cytokines2024 #KAI2024  

We are excited to highlight our Chief Medical Officer, Naiyer Rizvi, M.D., who has co-authored a significant journal article published in Nature Medicine!     Dr. Rizvi has been instrumental in shaping our clinical strategies and ensuring that we remain at the forefront of medical innovation. His insights have not only deepened our knowledge but also advanced the understanding of others in the field of #immunotherapy for #cancer treatment. See the article here: https://lnkd.in/dfAzayre  

Headed to the #FierceBiotechSummit? Hear from our CEO, Debanjan Ray, at the “Fierce 15 – Where are They Now” panel, where he will join other past #Fierce15 honorees to discuss recent company milestones and share insights, experiences and visions for the evolving #biotech landscape. Gabrielle Masson, Adam Friedman, Liang Schweizer, Nolan Townsend, Fierce Life Sciences Events More here: https://bit.ly/3BoJ6qo

This Saturday, our Chief Scientific Officer, Martin Oft, M.D., will be sharing key insights from the Phase 1 study of STK-012, our first-in-class α/β-biased IL-2 partial agonist for the treatment of advanced solid tumors, at “The Promise of Interleukin-2 Therapy Conference” in Paris, France. Join us in hearing Dr. Oft discuss STK-012 and its potential to improve the treatment paradigm for patients with #cancer. Learn more: https://bit.ly/4fX4lz8

Today, we announced that the U.S. #FDA has granted Fast Track designation to SYNCAR-001 + STK-009, our CD19 #CART and orthogonal IL-2 investigational therapy, for the treatment of patients with severe, refractory systemic #lupus erythematosus (SLE), without the use of lymphodepletion.   Fast Track designation validates the urgent need for safer, more tailored therapies that offer the benefits of CAR-T without the added risks of #lymphodepletion. We’re highly encouraged by the FDA’s decision, which brings us one step closer to providing our novel treatment option to a broad SLE patient population. Learn more about the announcement here: https://lnkd.in/dNVPfgAB

#DYK Lung cancer is the leading cause of cancer death in the United States, accounting for an estimated 1 in 5 of all cancer deaths? On #WorldLungCancerDay, join us as we raise awareness and support the countless individuals and families impacted by lung cancer. Together, we can make a meaningful difference.   #LungCancer #WLCD2024

This week, Alex Azrilevich, Pharm.D., our Vice President, Clinical Development, will be presenting on the promising potential of STK-012, our first-in-class α/β-biased IL-2 partial agonist for the treatment of advanced solid tumors, at the Kidney Cancer Research Summit hosted by KidneyCAN. Learn more: https://bit.ly/45RjH3r #KCRS24 #KidneyCancer

Our Scientific Founder, K. Christopher Garcia, Ph.D., was recently awarded the 2024 Passano Award for his research on the structural and mechanistic biology of cell surface receptors and its implications for safer and more effective treatments. Dr. Garcia’s research is foundational in our efforts to develop novel therapeutics targeting cytokine signaling pathways. Join us in congratulating Dr. Garcia on this prestigious honor! Learn more: https://bit.ly/4bLMokL